SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Granules India shines as its arm gets USFDA’s nod for Vigabatrin for Oral Solution

27 Apr 2020 Evaluate

Granules India is currently trading at Rs. 173.35, up by 6.05 points or 3.62% from its previous closing of Rs. 167.30 on the BSE.

The scrip opened at Rs. 172.55 and has touched a high and low of Rs. 175.40 and Rs. 172.00 respectively. So far 13304 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 188.85 on 19-Feb-2020 and a 52 week low of Rs. 84.25 on 26-Jul-2019.

Last one week high and low of the scrip stood at Rs. 175.40 and Rs. 153.80 respectively. The current market cap of the company is Rs. 4253.56 crore.

The promoters holding in the company stood at 42.90%, while Institutions and Non-Institutions held 20.95% and 36.14% respectively.

Granules India’s wholly owned foreign subsidiary -- Granules Pharmaceuticals Inc (GPI) has received approval for its Abbreviated New Drug Application (ANDA) from the US Food and Drug Administration (US FDA) for Vigabatrin for Oral Solution USP, 500 mg. It is bioequivalent to the reference listed drug product (RLD), Sabril (vigabatrin) for Oral Solution, 500 mg, of Lundbeck Pharmaceuticals LLC.

Vigabatrin for Oral Solution (brand and generic) products had U.S. sales of approximately $255 million MAT for the most recent twelve months ending in February 2020 according to IQVIA Health. Granules now has a total of 27 ANDA approvals from US FDA (25 Final approvals and 2 tentative approvals).

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

661.90 7.50 (1.15%)
20-Apr-2026 09:27 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1676.00
Dr. Reddys Lab 1234.90
Cipla 1239.00
Zydus Lifesciences 947.70
Lupin 2332.55
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×